Core Insights - Shandong Boan Biotechnology Co., Ltd. has received approval from the National Medical Products Administration of China for its self-developed product, Bo Youjing (Aflibercept intravitreal injection solution), to treat adult neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1][2] - Boan Biotechnology plans to commercialize the product in collaboration with leading domestic ophthalmic pharmaceutical company, Oculis [1] - The company is also pursuing international market opportunities, having granted exclusive sales rights to Shenzhen Kexing Pharmaceutical Co., Ltd. in specific regions outside of mainland China, the EU, the UK, the US, and Japan [1] Company Performance - Boan Biotechnology's Bo Youjing is the fifth product approved in the last five years, showcasing the company's strong technical capabilities and efficient transformation from R&D to commercialization [2] - The company is projected to achieve a revenue of 730 million yuan in 2024, representing a year-on-year growth of 17.5%, with a net profit of 73.19 million yuan, marking a significant increase of 190 million yuan and the first annual profit [2] - The company is also advancing its innovative antibody development, focusing on key products such as BA1302 (anti-CD228 ADC), PR201 (PD-1/IL-2), PR203 (TL1A/IL-23 bispecific), BA1106 (non-IL-2 blocking anti-CD25 antibody), BA1304 (EGFR/B7H3 ADC), and BA1301 (anti-Claudin18.2 ADC) [2]